NZ583209A - 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 - Google Patents

2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Info

Publication number
NZ583209A
NZ583209A NZ583209A NZ58320908A NZ583209A NZ 583209 A NZ583209 A NZ 583209A NZ 583209 A NZ583209 A NZ 583209A NZ 58320908 A NZ58320908 A NZ 58320908A NZ 583209 A NZ583209 A NZ 583209A
Authority
NZ
New Zealand
Prior art keywords
benzimidazole
methylpyrrolidin
carboxamide
crystalline form
group
Prior art date
Application number
NZ583209A
Other languages
English (en)
Inventor
Lawrence Kolaczkowski
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ583209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ583209A publication Critical patent/NZ583209A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ583209A 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 NZ583209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12
PCT/US2008/079441 WO2009049111A1 (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Publications (1)

Publication Number Publication Date
NZ583209A true NZ583209A (en) 2012-06-29

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583209A NZ583209A (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Country Status (28)

Country Link
US (4) US8372987B2 (enExample)
EP (2) EP2212327A1 (enExample)
JP (4) JP2011500589A (enExample)
KR (2) KR20100090769A (enExample)
CN (2) CN101821270A (enExample)
AU (1) AU2008310781B2 (enExample)
BR (1) BRPI0816221A8 (enExample)
CA (2) CA3006332A1 (enExample)
CO (1) CO6280493A2 (enExample)
CR (1) CR11368A (enExample)
DK (1) DK2722046T3 (enExample)
DO (1) DOP2010000099A (enExample)
EC (1) ECSP10010150A (enExample)
ES (1) ES2620299T3 (enExample)
GT (1) GT201000080A (enExample)
MX (1) MX350019B (enExample)
MY (1) MY156691A (enExample)
NZ (1) NZ583209A (enExample)
PA (1) PA8798401A1 (enExample)
PH (1) PH12012501636A1 (enExample)
PL (1) PL2722046T3 (enExample)
PT (1) PT2722046T (enExample)
RU (2) RU2476434C2 (enExample)
SG (1) SG185297A1 (enExample)
TW (1) TWI422588B (enExample)
UA (2) UA101961C2 (enExample)
WO (1) WO2009049111A1 (enExample)
ZA (1) ZA201002090B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) * 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Also Published As

Publication number Publication date
CN105367554A (zh) 2016-03-02
DK2722046T3 (en) 2017-03-20
BRPI0816221A8 (pt) 2015-09-22
PT2722046T (pt) 2017-03-15
CR11368A (es) 2010-10-25
US20150148392A1 (en) 2015-05-28
AU2008310781B2 (en) 2013-03-28
GT201000080A (es) 2012-04-03
TW200932747A (en) 2009-08-01
US20090099245A1 (en) 2009-04-16
CO6280493A2 (es) 2011-05-20
CA3006332A1 (en) 2009-04-16
EP2212327A1 (en) 2010-08-04
PH12012501636A1 (en) 2015-07-10
JP2011500589A (ja) 2011-01-06
US8372987B2 (en) 2013-02-12
PL2722046T3 (pl) 2017-06-30
MX2010003772A (es) 2010-04-21
ZA201002090B (en) 2011-11-30
SG185297A1 (en) 2012-11-29
AU2008310781A1 (en) 2009-04-16
MX350019B (es) 2016-12-09
EP2722046A1 (en) 2014-04-23
ECSP10010150A (es) 2010-06-29
CA2696424C (en) 2018-07-10
RU2476434C2 (ru) 2013-02-27
EP2722046B1 (en) 2016-12-21
PA8798401A1 (es) 2009-05-15
US8835647B2 (en) 2014-09-16
US20140024838A1 (en) 2014-01-23
KR20100090769A (ko) 2010-08-17
KR20160039312A (ko) 2016-04-08
MY156691A (en) 2016-03-15
US20130123317A1 (en) 2013-05-16
JP2017071618A (ja) 2017-04-13
UA113277C2 (xx) 2017-01-10
CA2696424A1 (en) 2009-04-16
TWI422588B (zh) 2014-01-11
UA101961C2 (xx) 2013-05-27
CN101821270A (zh) 2010-09-01
US9580410B2 (en) 2017-02-28
JP2019001811A (ja) 2019-01-10
ES2620299T3 (es) 2017-06-28
JP2014237659A (ja) 2014-12-18
DOP2010000099A (es) 2017-04-30
BRPI0816221A2 (pt) 2015-06-16
RU2010116397A (ru) 2011-11-20
WO2009049111A1 (en) 2009-04-16
RU2012147692A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
US9580410B2 (en) 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1
EP2727921B1 (en) 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2
US7772404B2 (en) Crystalline form 2 of the chemotherapeutic N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea
US7960564B2 (en) Crystalline chemotherapeutic
US7994208B2 (en) Crystalline chemotherapeutic
US8486988B2 (en) Crystalline chemotherapeutic
US8759538B1 (en) Crystalline chemotherapeutic
HK1197642B (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
HK1197642A (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ABBVIE BAHAMAS LTD., BS

Effective date: 20131212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2016 BY THOMSON REUTERS

Effective date: 20150922

ASS Change of ownership

Owner name: ABBVIE IRELAND UNLIMITED COMPANY, IE

Effective date: 20160915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2017 BY THOMSON REUTERS

Effective date: 20160909

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2018 BY THOMSON REUTERS

Effective date: 20170919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2019 BY THOMSON REUTERS

Effective date: 20180917

LAPS Patent lapsed